Sinclair IS Pharma non-execs subscribe for placing shares
2nd May 2014 15:55
Stuart Swanson, a non-executive director of AIM-listed Sinclair IS Pharma on Friday subscribed for just under 3.13m shares as part of a placing that was on Thursday approved by shareholders to support the acquisition of Silhouette, an aesthetics company. The deal followed a purchase made earlier
Read moreHuntsworth's half-way profits decline
8th Aug 2013 09:32
Public relations and healthcare communications group Huntsworth reported a drop in first half profits on flat revenues. Pre-tax profit fell to £10.6m from £11.6m while operating profits declined to £12.4m from £13.7m. Revenues rose a modest 0.8% to £88.9m. The company said results were in line wit
Read moreTuesday broker round-up UPDATE
21st May 2013 07:12
Antofagasta: Canaccord Genuity reduces target price from 1065p to 1040p, while leaving its hold recommendation unchanged. Barratt Developments: Goldman Sachs takes target price from 351p to 371p maintaining a buy recommendation. Big Yellow Group: Investec increases target price from 370p to 430p a
Read moreHuntsworth gains Chinese backing in return for 20 per cent stake
25th Apr 2013 12:57
Public relations group Huntsworth has signed a strategic alliance with "Asia's largest public relations group" BlueFocus Communications, which is investing 36.5m pounds into the UK company. After purchasing 63m of new shares at a 10.5% premium to their previous closing price, BlueFocus will own a 1
Read moreThursday broker round-up UPDATE
25th Apr 2013 09:07
Barclays: Morgan Stanley lowers target price from 438p to 424p and reiterates an overweight rating. Bellzone Mining: Investec reduces target price from 21p to 5.28p and downgrades to hold. BG Group: Bank of America cuts target price from 1300p to 1250p retaining a neutral rating. Brown (N) Group:
Read moreHuntsworth's non-executive director leaves for Acer
14th Dec 2012 14:37
Huntsworth announced Friday the resignation of its Non-Executive Director Michael Birkin, along with a number of changes to its board. The global public relations and healthcare communications group said Birkin will leave the company Friday to concentrate on his new commitments in Asia as Chief Ma
Read moreTuesday broker round-up UPDATE
20th Nov 2012 07:17
Beowulf Mining: Seymour Pierce initiates coverage with a buy recommendation and a target price of 18p. Berkeley Group: JP Morgan raises target price from 1616p to 1620p, overweight rating kept. Blinkx: Citigroup downgrades from buy to neutral. Compass Group: Investec raises target price from 740p
Read moreTuesday broker round-up
11th Sep 2012 09:29
3i Group: Oriel Securities downgrades to hold. AB Foods: HB Markets upgrades to buy. ARM Holdings: UBS raises target from 645p to 750p, buy rating kept. ASOS: Investec upgrades from hold to buy, 2,450p target kept. Bunzl: Goldman Sachs downgrades to sell, target cut from 978p to 965p. Burberry:
Read moreHuntsworth's global approach paying off
15th Aug 2012 15:17
Strong cost control and a change in the revenue mix enabled public relations and healthcare communications specialist Huntsworth to crank up first half profits despite flat revenues. Turnover in the six months to the end of June at £107.1m was barely changed from the £108.0m racked up in the first
Read moreWednesday broker round-up
15th Aug 2012 09:47
AB Foods: UBS raises target from 1,330p to 1,400p, buy rating unchanged. AVEVA: Jefferies ups target from 1,800p to 2,300p, buy recommendation maintained. Balfour Beatty: Investec maintains sell rating and 210p target. CLS Holdings: Peel Hunt ups target from 639p to 720p, hold rating kept. CRH:
Read moreBad end to 2011 dents Huntsworth full year numbers
3rd Apr 2012 08:19
Public relations and healthcare communications specialist, Huntsworth, says cancellation of contracts in the final three months of 2011 reduced full year revenues and profits. Group revenues rose by 1.5% to £176.3m versus £173.6m in 2010. The consensus expectation was £177.87m. Operating profits a
Read moreMonday broker round-up - UPDATE
12th Dec 2011 09:30
Xstrata: UBS cuts target from 1,550p to 1,450p, buy rating unchanged AstraZeneca: Credit Suisse reiterates underperform rating and 2,600p target. Standard Chartered: Investec reduces target from 1,650p to 1,550p, hold rating maintained. British American Tobacco: Investec raises target from 3,100p
Read moreWednesday broker round-up - UPDATE
23rd Nov 2011 09:22
Compass: Seymour Pierce reiterates buy rating and 650p target. Compass: Investec maintains buy and 630p target. Compass: Evolution Securities keeps buy rating and 640p target. Meggitt: UBS downgrades from neutral to sell, target cut from 340p to 330p. SABMiller: Investec upgrades from hold to bu
Read moreHammerson finance boss lays foundations
15th Sep 2011 15:08
The finance boss of Hammerson Timon Drakesmith has upped his stake in the shopping centre owner, spending nearly £200,000 on shares. He bought 50,000 shares in the company, paying 384.99p a time. Drakesmith will be glad he didn't rush into buying the shares following his appointment in June. They
Read moreBrammer bosses buy into placing
8th Sep 2011 15:00
Brammer's chief executive Ian Fraser and finance boss Paul Thwaite have together spent nearly £100,000 on shares in the distributor of motors, gearboxes, sprockets and other industrial products. They both took 20,833 shares at 240p a time. Fraser now has 1,365,876 shares, or about 1.2% of the compa
Read more